Clinical Supply in Asia-Pacific: Planning for China, Japan, Korea, and Australia

Asia-Pacific has become central to global development. China and South Korea run large numbers of trials, Japan matters for registration, and Australia is a favorite for early-phase studies. Sponsors who add APAC countries to a global trial often treat the region as one block. It is not. Each country has its own import rules, labeling expectations, and timelines, and a supply plan that works for Australia can fail badly in China.

Australia: fast start, distance problem

Australia's Clinical Trial Notification scheme lets studies start quickly, which is why so many first-in-human trials run there. Import is relatively straightforward, but distance is the issue. Shipments from the US or Europe take time and cross hot transit hubs, so lane qualification matters. Many sponsors use a local depot to hold stock in-country and keep resupply fast.

China: plan for import controls and genetic resource rules

China's market has grown fast, and its regulators have modernized, but import of investigational product still needs careful planning. Customs clearance requires specific documentation, and port inspection can add days. Sponsors usually work with an in-country depot and a local importer of record.

China's rules on human genetic resources also affect supply indirectly. Biological samples leaving the country need approvals, which matters if your kits include lab sample collection with central testing abroad. Plan this with the clinical and lab teams early.

Chinese language labeling is required. If China joins a global study late, a booklet label may need a new page, or kits may need relabeling in-country.

Japan: high standards, little tolerance for gaps

Japan expects detailed documentation and consistent quality. Clinical trial notifications go through the PMDA, and drug imports need a specific certificate process. Japanese labeling is required, and Japanese sites tend to expect clean, well-presented packaging. Damaged or poorly labeled kits get rejected more often than elsewhere.

Japan often joins global trials as part of a strategy for local registration, sometimes with a Japan-specific cohort. That can mean separate supply planning for a cohort with different enrollment timing.

South Korea: fast enrollment, high site concentration

South Korea enrolls quickly, with large academic hospitals in Seoul running many trials. Enrollment can outpace forecasts, so resupply needs to be fast. Import approvals for investigational products go through the MFDS, and Korean labeling is required. An in-country or nearby regional depot helps keep up with fast enrollment.

Taiwan, Singapore, and Southeast Asia

Taiwan and Singapore are well-organized trial markets with clear rules. Thailand, Malaysia, Vietnam, and the Philippines are growing but often need more lead time for import permits, which may be issued per shipment. Check permit validity and quantity rules before you plan resupply frequency.

Depot strategy for the region

A single regional hub (often Singapore) can serve several smaller markets, but China, Japan, and Korea frequently justify their own in-country depots because of import complexity and volume. A common model:

• In-country depots for China, Japan, and Korea.
• A regional hub in Singapore for Southeast Asia, Taiwan, and sometimes Australia.
• A local depot in Australia if volume or distance justifies it.

Weigh the cost of each extra depot against import timelines and resupply speed.

Labels for the countries you will have

The most expensive APAC supply mistake is printing labels for the original country list and then adding countries later. Leave room in booklet labels for likely additions, or plan for in-country or depot-level relabeling. Agree on the label strategy with regulatory before printing, because Asian languages can take more space than you expect.